These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9783674)

  • 1. Tumour necrosis factor: strategies for improving the therapeutic index.
    Corti A; Marcucci F
    J Drug Target; 1998; 5(6):403-13. PubMed ID: 9783674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for improving the anti-neoplastic activity of TNF by tumor targeting.
    Corti A
    Methods Mol Med; 2004; 98():247-64. PubMed ID: 15064445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.
    Gasparri A; Moro M; Curnis F; Sacchi A; Pagano S; Veglia F; Casorati G; Siccardi AG; Dellabona P; Corti A
    Cancer Res; 1999 Jun; 59(12):2917-23. PubMed ID: 10383155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects.
    Gerspach J; Pfizenmaier K; Wajant H
    Biofactors; 2009; 35(4):364-72. PubMed ID: 19484741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
    van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
    Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor, cancer and anticancer therapy.
    Mocellin S; Rossi CR; Pilati P; Nitti D
    Cytokine Growth Factor Rev; 2005 Feb; 16(1):35-53. PubMed ID: 15733831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
    Curnis F; Sacchi A; Corti A
    J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application.
    van Der Veen AH; ten Hagen TL; de Wilt JH; van Ijken MG; Eggermont AM
    Anticancer Res; 2000; 20(5B):3467-74. PubMed ID: 11131649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
    van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM
    Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor therapeutics by design: targeting and activation of death receptors.
    Wajant H; Gerspach J; Pfizenmaier K
    Cytokine Growth Factor Rev; 2005 Feb; 16(1):55-76. PubMed ID: 15733832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observations with tumour necrosis factor gene-transfected tumours.
    Blankenstein T
    Folia Biol (Praha); 1994; 40(1-2):19-28. PubMed ID: 7958061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor: clinical relevance.
    Jones AL; Selby P
    Cancer Surv; 1989; 8(4):817-36. PubMed ID: 2701729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
    Younes A; Kadin ME
    J Clin Oncol; 2003 Sep; 21(18):3526-34. PubMed ID: 12972530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
    Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
    Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor necrosis factor: pleiotropic cytokine].
    Chouaib S; Robinet E; Zyad A; Branellec D
    Bull Cancer; 1992; 79(10):935-49. PubMed ID: 1292760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents.
    ten Hagen TL; Eggermont AM
    Int J Hyperthermia; 2006 May; 22(3):241-6. PubMed ID: 16754345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor and cancer treatment: a historical review and perspectives.
    Terlikowski SJ
    Rocz Akad Med Bialymst; 2001; 46():5-18. PubMed ID: 11780579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
    Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
    Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.